Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. Founded in 2012

Welcome Guest \\ Login

MultiBacMam Compatible Cells

Compatibility of Mammalian Cells for Transduction

Human cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• 143B (osteosarcoma, ATCC CRL-8303)
• 39
• >90%
• 143TK- (fibroblast)
• 10
• N/A
• A549 (ATCC CCL-185, lung carcinoma)
• 41
• N/A
• BGC-823 (gastric carcinoma)
• 39
• 80%
• Bone marrow fibroblasts
• 5
• N/A
• C3A liver cells
• 29
• N/A
• Cal-51 (human mammary carcinoma)
• M. Mueller, U. Heidelberg
• 50% – 60%
• CHP212 (neuroblastoma)
• 9
• N/A
• Colo-205 epithelial cells
• C. Henery, Amnis Corp.
• 70% – 80%
• CRL-1973 (NTERA-2, Nt-2; embryonal carcinoma)
• 4, Molecular Probes
• N/A
• DLS-1
• 13
• N/A
• DMS 114 (ATCC CRL-2066, small cell lung carcinoma)
• 39
• 80%
• EA.hy926 (hybridoma of HUVEC and A549)
• 41
• 10% – 70%
• Embryonic lung fibroblasts
• 11
• N/A
• FLC4 (human hepatocarcinoma)
• 15
• N/A
• Glioma
• Genetech, 28, 35, 46, 50
• 80% – 90%
• HEK 293
• 2,5,15,27,39
• >90%
• HeLa
• 4,5,9,15,18,19,39
• 60% – >90%
• HepG2 (ATCC HB-8065, hepatocellular carcinoma)
• 1,2,15,34, 39, 47
• >90%
• HuH-7 (hepatoma)
• 1,4,5,15,19, 53
• >90%
• Human adipose mesenchymal stem cells (MSC)
• Geneva Biotech
• >90%
• Human bone-marrow mesenchymal stem cells (MSC)
• Geneva Biotech
• 80%
• Human dendtric cells
• 25
• 15%
• Human embryonic stem cells (HES)
• Geneva Biotech, 30
• 25% – 80%
• Human embryonic neural stem cells
• 9
• 30%
• Human inducible pluripotent stem cells (iPSC)
• 54
• >70
• Human mesenchymal stem cells (MSC)
• 20, 49
• 70%
• IMR-32 neuroblastoma (ATCC CCL-127)
• 4,32
• N/A
• K-562 (ATCC CCL-243, chronic myelogenous leukemia)
• Geneva Biotech
• >80%
• KATO-III (HTB-103, gastric carcinoma)
• 4
• N/A
• Keratinocytes
• 5
• N/A
• LNCaP (human prostatic adenocarcinoma)
• F.Matthieu, U. Science et technologies de Lille
• N/A
• MCF7 (ATCC HTB-22D, breast cancer cell line)
• NIH-NCI, 39
• >80%
• MG63 (ATCC CRL-1427, osteosarcoma)
• 5
• >90%
• MRC-5 (lung fibroblast)
• 7, 53
• N/A
• Pancreatic b-cells
• 8
• N/A
• PLC/PRF/5 (hepatoma; ATCC CRL-8024)
• 39
• >90%
• Prenatal cardiomyocytes (hCM)
• 18
• N/A
• Primary bone marrow fibroblasts
• 5
• 80%
• Primary dendritic cells
• 25
• N/A
• Primary human aortic smooth muscle cells (HASMC)
• Cascade Biologics
• >80%
• Primary human astrocytes (T98G and U373-MG)
• 9, 58
• >50%
• Primary human cardiomyocytes
• 18
• 90%
• Primary human chondrocytes
• NIH
• N/A
• Primary human coronary artery endothelia cells (HCEC)
• 18
• 40%
• Primary human coronary smooth muscle cells (HCASMC)
• 18
• 80%
• Primary human dermal fibroblasts – adult (HDFa)
• Cascade Biologics
• >90%
• Primary human dermal fibroblasts – neonatal (HDFn)
• Cascade Biologics
• >90%
• Primary human fibroblasts (HFB)
• 18, Cascade Biologics
• >90%
• Primary human foreskin fibroblasts (HFF)
• 5, 12, 28
• 30%
• Primary human glial cells
• 9
• ~60%
• Primary human hepatic stellate cells
• 19, 23
• 90%
• Primary human hepatocytes
• 1, 2, 5, Molecular Probes
• >90%
• Primary human keratinocytes (HEK)
• 5, Cascade Biologics
• >90%
• Primary human lung fibroblasts
• NIH
• N/A
• Primary human mammary epithelial cells (HMEC)
• Cascade Biologics
• >90%
• Primary human melanocytes
• Geneva Biotech
• >90%
• Primary human neuoepithelial and neuroblastic cells
• 9
• N/A
• Primary human pancreatic islet cells
• 8
• N/A
• Primary umbilical vein endothelial cells (HUVEC)
• 54, 28, Geneva Biotech
• 90%
• Saos-2
• 5,6,19, 38
• >90%
• SHSY-5Y (neuroblastoma)
• 27,29
• N/A
• SK-BR-3
• Molecular Probes
• N/A
• SK-N-MC
• 5
• >90%
• SK-OV-3 (ATCC HTB-77, adenocarcinoma)
• 50
• N/A
• T47D (breast carcinoma)
• 36
• N/A
• U-2 OS
• 27, Molecular Probes
• >90%
• W12 (human cervical keratinocyte)
• 5
• >90%
• WI38 (human lung fibroblast)
• 5, 39
• >90%

Non-human primate cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• COS-7 (African green monkey kidney fibroblast-like cells)
• 3,4,5,9, Molecular Probes
• >90%
• CV-1 (African green monkey kidney fibroblast cells)
• 5,15, 39, Molecular Probes
• >90%
• Vero
• 14, A.Snyder, OHSU
• 50%

Bovine cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• MDB (bovine kidney) epithelial cell line
• 5
• N/A
• BT (bovine turbinate) epithelial cell line (ATCC CRL-1390)
• 5
• N/A

Ovine (Sheep) cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• FLL-YFT (fetal lamb lung) cell line
• 5
• N/A

Cervidae (Deer) cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• Indian Muntjac deer epidermis cell line
• M.Davidson, Molecular Expressions Inc.
• N/A

Suis (Pig) cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• CPK (porcine kindney)
• 4,5
• N/A
• FS-L3 (porcine kidney) epithelial cell line
• 4,5
• N/A
• PK-15 (porcine kidney; ATCC CCL-33)
• 5,34
• N/A
• Left atrial appendage progenitor cells – adult stem cells
• M.Rutten and K.Gregory, OMLC
• N/A
• Porcine coronary artery smooth muscle cells (pCSMC)
• 18
• LLC-PK1 (kidney proximal tubule) cell line
• 27, 56
• >50%
• Primary Cardiac Smooth Muscle Cells
• M.Rutten and K.Gregory, OMLC
• N/A

Carnivores

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• FoLu (Gray fox lung fibroblasts)
• M. Davidson, Molecular Expressions Inc.
• N/A
• MDCK (NBL-2; dog kidney)
• Molecular Probes
• N/A

Marsupials

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• OK (opossum kidney) epithelial cell line
• M.Davidson, Molecular Expressions Inc.
• N/A

Hamster cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• CHO (Chinese hamster ovary K1, M1WT3, hIR)
• 5,15,31, Molecular Probes
• 75% – >90%

Mouse cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• 3T3 mouse fibroblasts
• 23, 38, 39, Geneva Biotech
• 15% – 80%
• BNL 1ME A7.7R.1 (ATCC TIB-75, mouse liver carcinoma)
• 39
• 75%
• C2C12 (myoblast)
• 51
• 60%
• Dendritic cells
• 36
• 15%
• GnRH neuronal cells
• S.Singh, Johns Hopkins
• 60% – 70%
• JC (adenocarcinoma)
• 39
• 20%
• L929 (ATCC CCL-1, subcutaneous connective tissue)
• 39
• 35%
• MEF
• 54,57, 59
• >70%
• Neuroblastoma (N2a)
• 9
• N/A
• P388D1 (ATCC CCL-46, lymphoma)
• 5
• 25%
• Primary kidney cells
• 22
• N/A
• Primary pancreatic acinar cell
• Geneva Biotech
• N/A
• Primary pancreatic islet cells
• 8
• 85%
• Primary retinal cells
• 55
• NA
• Primary ventricular cardiomyocytes
• Geneva Biotech
• >90%
• PT67 (embryo fibroblast)
• 39
• 10%
• Sol 8 (myoblast)
• 51
• 75%

Potoroo (Rat Kangaroo) cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• Ptk2
• M.Davidson, Molecular Expressions Inc.
• N/A

Rabbit cells

• CELL TYPE
• REFERENCE (see below)
• TRANSDUCTION %
• CRL-2560 (RH/K30, MT-2; rabbit T-cell line)
• 4
• N/A
• Primary aortic smooth muscle cells (RaASMC)
• 41
• 40% – 75%
• Primary chondrocytes
• 44
• >75%
• Primary chondrocytes (intervertebral disc nucleus)
• 24
• 85%
• Primary hepatocytes
• 16
• N/A
• RK13 (normal rabbit kidney epithelial cells)
• C. Harrison, Univ. Melbourne
• >80%

Rat cells

• BHK
• 5,15,34
• N/A
• Brain choroid plexus cells (in vivo)
• 40
• 60% – >90%
• Brain pericytes cell line
• Molecular Probes
• N/A
• C17.2 cells (multipotent neural stem cell line)
• 31
• N/A
• Neural stem cells
• A.Moutri, Salk Institute
• 30%
• PC12
• 4,5
• 20%
• Primary cerebellar granule neurons
• 31
• N/A
• Primary chondrocytes
• 21, 42, 45
• 85%
• Primary cortical neurons
• 54, Geneva Biotech
• >90%
• Primary dissociated dorsal root ganglion neurons
• 55
• >80%
• Primary glial cells (astrocytes)
• 48
• 60% – 80%
• Primary hepatic stellate cells
• 23
• Primary hepatocytes
• 2
• N/A
• Primary myoblasts
• 51
• 75%
• Primary rat tendon fibroblasts
• K. Gardner, Michigan State Univ.
• N/A
• Primary spiral ganglion neurons
• 33
• N/A
• Rat2
• M.Davidson, Molecular Expressions Inc.
• REF(rat embryo fibroblast)
• 54
• >70%
• RGM I
• 4
• N/A
• T6 (rat hepatic stellate cell line)
• 23
• 20%

Zebrafish

• Zebrafish
• 54,55
• N/A

References forBacMam-mediated Transduction of Mammalian Cells

• 1. Hofmann, C. et al. (1995) Proc. Natl. Acad. Sci. USA 92:10099-10103.
• Link
• 2. Boyce, F.M. & Boucher, N. (1996) Proc. Natl. Acad. Sci. USA 93:2348-2352
• Link
• 3. Yap, C.-C. et al. (1997) Virology 231:192-200
• Link
• 4. Shoji, I. et al. (1997) J. Gen. Virol. 78:2657-2664
• Link
• 5. Condreay, J.P. et al. (1999) Proc. Natl. Acad. Sci. USA 96:127-132
• Link
• 6. Merrihew, R.V. et al. (2001) J. Virol. 75:903-909
• Link
• 7. Palambo, F. et al. (1998) J. Virol. 72:5025-5034
• Link
• 8. Ma, L. et al. (2000) Diabetes 49:1986-1991
• Link
• 9. Sarkis, C. et al. (2000) Proc. Natl. Acad. Sci USA 98:14638-14643
• Link
• 10. Ye, G.J. et al. (2000) J. Virol. 74:1355-1363
• Link
• 11. Lopez, P. et al. (2001) J. Virol. 75:3832-3840
• Link
• 12. Dwarakanath, R.S. et al. (2001) Virology 284:297-307
• Link
• 13. Barsoum, J. et al. (1997) Hum. Gene Ther. 8:2011-2018
• Link
• 14. Airenne, K.J. et al. (2000) Gene Ther. 7:1499-1504
• Link
• 15. Tani, H. et al. (2001) Virology 279:343-353
• Link
• 16. Munger, J. &Roizman, B. (2001) Proc. Natl. Acad. Sci. USA 98:10410-10415
• Link
• 17. Ames, R.S. et al. (2004) Receptors Channels 10:117-124
• Link
• 18. Grassi, G. et al. (2006) Arch. Virol. 151:255-271
• Link
• 19. Nicholson, L.J. et al. (2005) Mol. Ther. 11:638-644
• Link
• 20. Ho, Y.-C. et al. (2005) J. Gene Med. 7:860-868
• Link
• 21. Ho, Y.-C. et al. (2004) Biotechnol. Bioeng. 88:643-651
• Link
• 22. Liang, C.Y. et al. (2004) Arch. Virol. 149:51-60
• Link
• 23. Gao, R. et al. (2002) Liver 22:15-22
• Link
• 24. Liu, X. et al. (2006) Spine 31:732-5
• Link
• 25. Strauss, R. et al. (2007) Mol. Ther. 15:193-202
• Link
• 26. Leisy, D.J. et al. (2003) J. Gen. Virol. 84:1173-8
• Link
• 27. Hassan, N.J. (2006) Prot. Expr. Purif. 47:591-8
• Link
• 28. Kronschnabl, M. &Stamminger, T. (2003) J. Gen. Virol. 84:61-73
• Link
• 29. Andersson, M. et al. (2007) BMC Cell Biol. 8:6-16
• Link
• 30. Zeng, J. et al. (2007) Stem Cells 25:1055-1061
• Link
• 31. Li, Y. et al. (2004) Exp. Physiol. 90:39-44
• Link
• 32. Näsman, J. et al. (2006) J. Neurosci. 26:10658-10666
• Link
• 33. Wang, J. et al. (2006) Neuro Report 18:1329-1333
• Link
• 34. Gao, H. et al. (2007) J. Biotechnol. 131:138-143
• Link
• 35. Wang, C.Y. et al. (2006) Cancer Res. 66:5798-5806
• Link
• 36. Ping, W. et al. (2006) Avian Dis. 50:59-63
• Link
• 37. Long, G. et al. (2006) J. Virol. 80:8830-8833
• Link
• 38. Song, S.U. and Boyce, F.M (2001) Exp. Mol. Med. 33, 46–53
• Link
• 39. Cheng T et al. (2004) World J. Gastroenterol. 10:1612–18
• Link
• 40. Laitinen, O.H. et al (2005) NAR 33:e42
• Link
• 41. Mähönen, A.J. et al. (2007) J. Biotechnol. 131:1-8
• Link
• 42. Lee, H.-P. et al. (2007) J. Gene Med. 9:33-43
• Link
• 43. Wagle, L. &Jesuthasan, S. (2003) Mar. Biotechnol. 5:58-63
• Link
• 44. Shen, H.-C. et al. (2007) J. Gene Med. 9:470-478
• Link
• 45. Chan, Z.-R. et al. (2005) Biotechnol. Bioeng. 93:565-571
•  
• 46. Lacker, A. et al. (2008) Anal. Biochem. 380:146-148
• Link
• 47. Matalainen, H. et al. (2005) J. Virol. 79:15452-15459
• Link
• 48. Wang, C.Y. and S. Wang (2006) Gene Ther. 13:1447-1456
• Link
• 49. Chuang, C.-K. et al. (2007) Gene Ther. 14:1417-1424
• Link
• 50. Kaikkonen, M.U. et al. (2006)Gene Ther.
• Link
• 51. Shen, H.-C. et al. (2008) J. Gene Med. 10:1190-1197
• Link
• 52. Lehtolainen, P. et al. (2002) Gene Ther. 9:1693-1699
• Link
• 53. Palombo, F. et al. (1998) J. Virol. 72:5025-5034
• Link
• 54. Mansouri, M. et al. (2016) Nature Communications.
• Link
• 55. Levin, E. et al. (2016) Science Reports
• Link
• 56. Fung, K. et al. (2016) Drug MetabDispos
• Link
• 57. Xie, W. et al. (2015) PLoS One
• Link
• 58. Fassina, L. et al. (2012) Eur J. Histochem
• Link
• 59. Takata, Y. et al. (2011) Cell StructFunct
• Link

Research Highlights

View all

Follow us on LinkedIn

Contact Us

//